Phathom Pharmaceuticals appoints Frank Karbe to board of directors

Phathom Pharmaceuticals, Inc.

Frank Karbe appointed as Class II director effective April 25, 2022; will serve on audit and compensation committees.
Karbe previously served as President and CFO of Myovant Sciences, and EVP and CFO of Exelixis.
Received option to purchase 20,000 shares of common stock with three-year vesting, plus cash compensation.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Frank Karbe

Director

PHAT · Phathom Pharmaceuticals, Inc.

Effective: 2022-04-25
Filed: April 26, 2022, 7:59 PM ET

On April 25, 2022, the board of directors (the “Board”) of Phathom Pharmaceuticals, Inc. (the “Company”) appointed Frank Karbe to the Board as a Class II director, effective immediately

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Frank Karbe was appointed as Director at Phathom Pharmaceuticals, Inc..

Action: appointed
Role: Director

Exact text from the filing

On April 25, 2022, the board of directors (the “Board”) of Phathom Pharmaceuticals, Inc. (the “Company”) appointed Frank Karbe to the Board as a Class II director, effective immediately

View on SEC.gov

Phathom Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-118940

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.